CUV 2.47% $14.95 clinuvel pharmaceuticals limited

Ann: CLINUVEL Newsletter IV - October 2023, page-9

  1. 21 Posts.
    lightbulb Created with Sketch. 2
    “Disc should probably raise a bit of funding and offer cash/shares to take over CUV”

    I don’t see how this would be plausible, Silverchair. They’d have to have to raise a hell of a lot more than what they’re worth to match a price CUV management and shareholders would accept. Could you expand on your suggestion?

    Also, do you have any opinions as to why CUV is supposedly being shorted so consistently for so long? What would the motive be, as the direct profit from the process couldn’t be that significant compared to the perceived risk?
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.